Handyladegeraet

Eintrag vom: 27.09.2013.

Maridebart cafraglutide (MariTide formerly AMG 133) is an antibody-peptide conjugate that activates the glucagon-like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR). It is being investigated for the treatment of obesity.

 

Fresh out of the gates with $500 million in financing neuroscience-focused Neumora Therapeutics forged a strategic partnership with Amgen to develop and commercialize assets owned by the pharma giant targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases.

 

Arch Venture Partners has taken the lid off its big bet on neuroscience. Having quietly put the startup together over the past 18 months Thursday Arch unveiled Neumora Therapeutics?a biotech...

 

AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)

 

First and Only CD19-Targeted Therapy Approved in Europe for Adults with anti-AChR+ and anti-MuSK+ gMG UPLIZNA Demonstrates Durable Disease Control with Twice-Yearly Dosing* THOUSAND OAKS Calif. Feb. 12 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the European Commission (EC) has approved UPLIZNA ® (inebilizumab) as an add-on treatment to standard therapy for adults living with ...

 

MINT Study Results Show Clinically Meaningful and Statistically Significant Efficacy in AChR+ and MuSK+ Patients First and Only Phase 3 Placebo-Controlled gMG Trial for a Biologic That Tapered Corticosteroid Use THOUSAND OAKS Calif. Oct. 15 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the ...

 

The European Commission (EC) has approved the monoclonal antibody (mAb) inebilizumab (Uplizna; Amgen) as an add-on to standard therapy in the treatment of adults with generalized myasthenia gravis (gMG) in adults who are antiacetylcholine receptor (AChR) and antimuscle specific tyrosine kinase (MuSK) antibody positive. 1 The EC?s decision was based on data from the randomized double-blind ...

 

Neumora leverages proprietary multimodal capabilities and technologies to integrate advanced computational data science with R&D to increase the probability of success of drug development in brain...

 

In addition Neumora has received a $100 million equity investment from Amgen and acquired exclusive global rights to develop and commercialize Amgen programs targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases.